Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma.
head and neck squamous cell carcinoma
immunohistochemistry
immunotherapy
programmed death-ligand 1
radio-chemotherapy
systematic review
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
18 Feb 2023
18 Feb 2023
Historique:
received:
13
12
2022
revised:
14
01
2023
accepted:
17
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Programmed death-ligand 1 (PD-L1) checkpoint inhibitors represent a mainstay of therapy in head and neck squamous cell cancer (HNSCC). However, little is known about the influence of combined therapy on PD-L1 expression. The study aims to gather evidence on this topic. A systematic search was carried out in electronic databases Pubmed-MEDLINE and Embase to retrieve studies on the comparison of PD-L1 expression before and after conventional therapy. Data were extracted and a quantitative analysis with pooled odds ratios (ORs) was performed when applicable. Of 5688 items, 15 were finally included. Only a minority of studies assessed PD-L1 with the recommended combined positive score (CPS). The results are highly heterogeneous, with some studies reporting an increase in PD-L1 expression and others reporting a decrease. Three studies allowed for quantitative analysis and showed a pooled OR of 0.49 (CI 0.27-0.90). From the present evidence, a clear conclusion towards an increase or decrease in PD-L1 expression after combined therapy cannot be drawn, but even with few studies available, a trend towards an increase in expression in tumor cells at a cutoff of 1% can be noted in patients undergoing platinum-based therapy. Future studies will provide more robust data on the effect of combined therapy on PD-L1 expression.
Sections du résumé
BACKGROUND
BACKGROUND
Programmed death-ligand 1 (PD-L1) checkpoint inhibitors represent a mainstay of therapy in head and neck squamous cell cancer (HNSCC). However, little is known about the influence of combined therapy on PD-L1 expression. The study aims to gather evidence on this topic.
METHODS
METHODS
A systematic search was carried out in electronic databases Pubmed-MEDLINE and Embase to retrieve studies on the comparison of PD-L1 expression before and after conventional therapy. Data were extracted and a quantitative analysis with pooled odds ratios (ORs) was performed when applicable.
RESULTS
RESULTS
Of 5688 items, 15 were finally included. Only a minority of studies assessed PD-L1 with the recommended combined positive score (CPS). The results are highly heterogeneous, with some studies reporting an increase in PD-L1 expression and others reporting a decrease. Three studies allowed for quantitative analysis and showed a pooled OR of 0.49 (CI 0.27-0.90).
CONCLUSIONS
CONCLUSIONS
From the present evidence, a clear conclusion towards an increase or decrease in PD-L1 expression after combined therapy cannot be drawn, but even with few studies available, a trend towards an increase in expression in tumor cells at a cutoff of 1% can be noted in patients undergoing platinum-based therapy. Future studies will provide more robust data on the effect of combined therapy on PD-L1 expression.
Identifiants
pubmed: 36836595
pii: jpm13020363
doi: 10.3390/jpm13020363
pmc: PMC9965293
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Oncol. 2017 Aug;18(8):1104-1115
pubmed: 28651929
Mol Cell Biochem. 2020 Dec;475(1-2):79-91
pubmed: 32761300
Head Neck. 2021 Mar;43(3):778-787
pubmed: 33159481
Pathol Oncol Res. 2020 Apr;26(2):735-742
pubmed: 30767115
Cancer Sci. 2022 Feb;113(2):399-410
pubmed: 34773342
J Oral Pathol Med. 2021 Oct;50(9):864-873
pubmed: 34157159
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Onco Targets Ther. 2020 Nov 03;13:11221-11235
pubmed: 33173312
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
Oral Oncol. 2020 Jul;106:104722
pubmed: 32330687
Br J Surg. 2021 Jun 22;108(6):622-631
pubmed: 33963374
Oral Oncol. 2017 Apr;67:52-60
pubmed: 28351581
J Pers Med. 2022 Jun 29;12(7):
pubmed: 35887569
Clin Transl Sci. 2022 Jan;15(1):55-62
pubmed: 33742767
Diagnostics (Basel). 2022 Feb 13;12(2):
pubmed: 35204568
Head Neck. 2019 Aug;41(8):2484-2491
pubmed: 30821864
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Res. 2016 Mar 1;76(5):1031-43
pubmed: 26676749
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Histopathology. 2018 Sep;73(3):500-509
pubmed: 29768723
Pathol Res Pract. 2021 Oct;226:153605
pubmed: 34530257
Front Cell Dev Biol. 2019 Apr 09;7:52
pubmed: 31024913
Nature. 2022 Nov;611(7937):810-817
pubmed: 36385528
Cancer Lett. 2019 Nov 1;464:5-14
pubmed: 31404614
Head Neck. 2021 Aug;43(8):2457-2467
pubmed: 33893751
Nat Commun. 2021 Jun 7;12(1):3349
pubmed: 34099645
Ann Transl Med. 2021 Nov;9(22):1650
pubmed: 34988159
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Biomedicines. 2022 Dec 13;10(12):
pubmed: 36551992
Anticancer Res. 2019 Aug;39(8):4539-4548
pubmed: 31366557
Oral Oncol. 2021 Aug;119:105368
pubmed: 34111704
Oral Oncol. 2019 Dec;99:104460
pubmed: 31683169
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Oncol Rep. 2021 Mar;45(3):1273-1283
pubmed: 33432367
Endocr Pathol. 2020 Sep;31(3):291-300
pubmed: 32468210
Mod Pathol. 2021 Mar;34(3):532-541
pubmed: 33239737
ESMO Open. 2018 Jan 09;3(1):e000257
pubmed: 29344407
Mod Pathol. 2021 Jun;34(6):1125-1132
pubmed: 32759978
Clin Exp Dent Res. 2022 Jun;8(3):690-698
pubmed: 35593124
Sci Rep. 2020 Jul 20;10(1):11973
pubmed: 32686757
Br J Cancer. 2019 May;120(10):1003-1006
pubmed: 30967647
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Pathol Res Pract. 2022 Sep;237:154042
pubmed: 35926433
Eur Arch Otorhinolaryngol. 2022 Jan;279(1):343-351
pubmed: 33796940
Int J Mol Sci. 2021 May 12;22(10):
pubmed: 34066087
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Oral Oncol. 2020 Dec;111:104928
pubmed: 32738599
Oncologist. 2010;15(9):994-1001
pubmed: 20798198
Oncotarget. 2017 Jun 16;8(58):97920-97927
pubmed: 29228662
Proc Natl Acad Sci U S A. 2022 Oct 18;119(42):e2209044119
pubmed: 36227917
Transl Lung Cancer Res. 2020 Aug;9(4):1343-1360
pubmed: 32953509
Biosci Rep. 2019 Sep 6;39(9):
pubmed: 31341011
Nat Rev Cancer. 2023 Mar;23(3):173-188
pubmed: 36456755
Histopathology. 2022 Jan;80(2):397-406
pubmed: 34496080
Clin Cancer Res. 2019 Sep 1;25(17):5221-5230
pubmed: 31239321
Diagn Pathol. 2020 Jun 3;15(1):67
pubmed: 32493336
Oral Oncol. 2020 Jul;106:104719
pubmed: 32335324
Front Pharmacol. 2019 Aug 30;10:962
pubmed: 31616289
Sci Rep. 2020 Nov 18;10(1):20059
pubmed: 33208791